Core Viewpoint - The Chinese medicine industry is currently facing significant challenges, including regulatory changes that may lead to the elimination of many traditional Chinese medicine products, but this could also serve as an opportunity for industry upgrade and quality improvement [7][9][33]. Group 1: Industry Performance and Market Sentiment - After the "924" market trend in 2024, the Shenwan Chinese Medicine Index has been adjusted and has continued to consolidate, with a cumulative decline of over 10% [3]. - Even with performance forecasts indicating profit growth for Chinese medicine companies, the market has not responded positively, as seen with WoHua Pharmaceutical's net profit doubling yet experiencing a 6.01% drop in stock price the following day [4]. - The recent negative sentiment in the market is largely due to the impending withdrawal of a large number of traditional Chinese medicine products, as new regulations require clearer safety information on product labels [7][8]. Group 2: Regulatory Changes and Industry Impact - The new regulations state that any traditional Chinese medicine product with unclear safety information will not be approved for re-registration after July 1, 2026, affecting approximately 57,000 existing products, with over 70% facing safety information issues [7]. - The industry is experiencing a "compliance storm," which is seen not merely as a phase of elimination but as a catalyst for quality improvement and modernization of traditional Chinese medicine [9][11][33]. Group 3: Strategies for Development - To survive, companies must focus on supplementing safety data and revising product labels to ensure compliance with new regulations [15][16]. - Many leading companies have already completed the revision of their core products' labels, indicating a proactive approach to compliance [19]. - The compliance costs associated with these changes are manageable for companies with market support, as evidenced by several firms maintaining profitability despite the regulatory pressures [22][24]. Group 4: Innovation and Future Growth - Beyond compliance, companies need to invest in innovative research and development to ensure long-term growth, especially in a challenging market environment characterized by price reductions and weak consumer demand [27]. - New drug classifications in traditional Chinese medicine include ancient classic formulas, improved formulations, and innovative drugs, with the latter representing the highest potential for future competitiveness [28][30]. - Companies like Kangyuan Pharmaceutical and Shenwei Pharmaceutical are leading in innovation, having received multiple approvals for new products, indicating a focus on future growth opportunities [30][31].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603998 证券简称：方盛制药 公告编号：2026-008 湖南方盛制药股份有限公司 关于公司参与投资设立的并购基金对外出售投资 项目部分股份的进展公告 1、同系方盛已于近期召开合伙人会议，同意将其存续期延长一年至2027年1月31日，同意同系泰兴、同 系未来将其分别持有的同系方盛未实缴出资额31.70万元（实缴出资28.30万元）、285.30万元退伙（实 缴出资254.70万元），同系方盛认缴出资额由47,065.83万元减少为46,748.83万元； 2、根据此前约定，同系方盛在收回全部回购款项后不再持有湖南珂信股权；此外，目前武汉珂信6%的 股权已过户至同系方盛名下； 3、根据湖南珂信提供的长沙珂信相关数据，长沙珂信2025年度扣除非经常性损益后的净利润已达到向 盈康生命作出的首年业绩承诺目标，预计将触发盈康生命收购湖南珂信持有的长沙珂信29%股权的条 件，但具体交易尚需要各方履行相关审批程 ...

Core Viewpoint - Fangsheng Pharmaceutical (603998) emphasizes its focus on innovative traditional Chinese medicine (TCM) and classic TCM products, highlighting their clinical value and adherence to regulatory standards [1] Product Overview - The company’s main products include innovative TCM such as Xiaoer Jingxing Zhike Granules, Xuanqi Jianguo Tablets, and Yangxue Qufeng Zhitong Granules, all of which have undergone Phase II and III clinical trials [1] - Innovative TCM products are based on TCM theory and clinical practice, featuring breakthroughs in formulation, process, and standards, with strict quality control and minimal side effects due to their natural origins [1] - Classic TCM products include Tenghuang Jianguo Tablets, Xuesaitong Tablets/Dispersible Tablets, and Qiangli Pipa Syrup (Honey-Processed)/Liquid, which have completed or are in the process of revising safety content in their instructions [1] Regulatory Compliance - The company is attentive to regulatory policy adjustments in the TCM industry and prioritizes the safety and efficacy of its products, ensuring compliance with national drug regulatory requirements in its production and R&D activities [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-008 湖南方盛制药股份有限公司 关于公司参与投资设立的并购基金对外出售投资 项目部分股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、同系方盛已于近期召开合伙人会议，同意将其存续期延长一年至 2027 年 1 月 31 日，同意同系泰兴、同系未来将其分别持有的同系方盛未实缴出资额 31.70 万元（实缴 出资 28.30 万元）、285.30 万元退伙（实缴出资 254.70 万元），同系方盛认缴出资额由 47,065.83 万元减少为 46,748.83 万元； 2、根据此前约定，同系方盛在收回全部回购款项后不再持有湖南珂信股权；此外， 目前武汉珂信 6%的股权已过户至同系方盛名下； 3、根据湖南珂信提供的长沙珂信相关数据，长沙珂信 2025 年度扣除非经常性损益 后的净利润已达到向盈康生命作出的首年业绩承诺目标，预计将触 ...

湖南方盛制药股份有限公司 关于公司《药品生产许可证》变更的公告 湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2026-007 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）近期完成 了《药品生产许可证》的变更登记并取得了湖南省药品监督管理 局核发的《药品生产许可证》。现将相关情况公告如下： 一、《药品生产许可证》的变更内容 1、在生产地址湖南省长沙市麓松路 789 号新增生产范围： 贴剂（仅用于注册申报），所在车间生产线：贴膏剂一车间贴剂 生产线 1，上述剂型及车间生产线通过药品 GMP 符合性检查后 方可生产上市； 2、新增生产范围：原料药盐酸替扎尼定、盐酸乙哌立松， 仅用于注册申报，所在车间生产线：原料药一车间原料药生产线 1，上述品种转 A 并通过药品 GMP 符合性检查后方可生产上市。 二、变更后的《药品生产许可证》具体内容 许可证编号：湘 20150028 企业名 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 关于受让药品上市许可的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2025 年 3 月 25 日，湖南方盛制药股份有限公司（以下简称 "公司"）受让康溢医药有限公司（以下简称"康溢医药"）持 有的"喉咽清胶囊""浙贝止咳露（黄盒）"等合计 20 个在香 港特别行政区卫生署（以下简称"香港卫生署"）注册的药品品 种的所有权（详见公司 2025-030 号公告）；2025 年 6 月 3 日， 公司与自然人赵国灏先生、港捷有限公司（以下简称"港捷公司"）、 湖南科祺创新科技有限公司（以下简称"科祺创新"）与湖南筱 沐医药科技有限公司（以下简称"筱沐医药"）签订《投资合作 协议》，调整对香港合资子公司的股权结构（详见公司 2025-060 号公告）；2025 年 6 月 20 日，公司与康溢医药、自然人李明志 先生签订《药品品种转让协议之补充协议》，决定对《药品品种 转让协议 ...

方盛制药公告称，2026年1月28日，香港合资子公司香港方盛堂与相关方签订补充协议，新增注册资本 4500万港元，公司认购2705万港元，增资后持股比例由50%增至57%。除港捷公司外，各方根据生产经 营需求分期同比例实缴出资。目前，香港方盛堂正分批次对受让的20个药品品种进行技术升级，受让药 品变更手续在准备办理中。此次增资对公司经营及药品许可转让交易无重大影响，但药品内地上市注册 及后续研究评价、生产销售等存在不确定性。 ...

Group 1 - Spot gold price has surpassed $5000 per ounce for the first time, with institutions predicting it could rise to $6600 [2] - The recent surge in gold prices is attributed to U.S. President Trump's policies reshaping international relations and investors fleeing sovereign bonds and foreign exchange markets [2] - Last week, gold prices increased by 8.5%, driven by a weakening dollar, which has made gold and silver cheaper for global buyers [2] Group 2 - In the past two weeks, stock ETFs have seen a net outflow of nearly 500 billion yuan, with significant redemptions in broad-based ETFs [3] - The trading volume of stock ETFs has surged, with some broad-based ETFs reaching record highs since their inception [3] Group 3 - The semiconductor sector in A-shares has been active in mergers and acquisitions, with several companies announcing related plans and progress [8] Group 4 - The commercial aerospace sector is experiencing a talent shortage, with investors with relevant experience being highly sought after [9] - The market is facing a significant gap in experienced commercial aerospace investors, leading firms to recruit candidates with adjacent experience [9] Group 5 - Global commodity markets are entering a new super cycle, with fund managers strategically increasing allocations to non-ferrous and chemical products [10] - Factors such as global monetary expansion, a credit crisis in the dollar, and geopolitical conflicts are contributing to this anticipated cycle [10]

Core Viewpoint - The company has received approval for the production of Loxoprofen Sodium Gel Patch, which is expected to enhance its product line in orthopedic medications and improve its competitive position in the market [1][3]. Group 1: Drug Registration and Details - The company's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch from the National Medical Products Administration [1]. - Loxoprofen Sodium Gel Patch is indicated for the treatment of osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The total investment in this drug project, including research and development, has reached 7.0366 million yuan (approximately 1.01 million USD) as of the announcement date [1]. Group 2: Market Situation of Similar Drugs - A total of 15 companies in China have obtained drug registration certificates for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [2]. - According to Moen Pharmaceutical data, the total sales of Loxoprofen Sodium Gel Patch in hospitals for the first three quarters of 2025 reached 1.349 billion yuan (approximately 190 million USD), with retail sales in physical pharmacies amounting to 142 million yuan (approximately 20 million USD) in the first half of 2025 [2]. - Projected sales for 2024 are expected to be 1.709 billion yuan (approximately 240 million USD) in hospitals and 280 million yuan (approximately 40 million USD) in retail pharmacies [2]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch will enrich the company's product line for orthopedic diseases, which already includes products like Xuanqi Jianguo Tablets and Tenghuang Jianguo Tablets [3]. - This new product is anticipated to enhance the company's competitiveness in the orthopedic medication market and improve overall profitability [3]. - The company emphasizes the importance of drug research and development while maintaining strict quality control in the manufacturing and sales processes [3].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, allowing for production and sales, which enhances its product line in orthopedic medications and competitive position in the market [1][4]. Group 1: Drug Registration and Details - The Drug Registration Certificate for Loxoprofen Sodium Gel Patch was approved by the National Medical Products Administration on January 23, 2026 [1]. - Loxoprofen Sodium Gel Patch is indicated for osteoarthritis, muscle pain, and swelling pain after injuries, with significant anti-inflammatory and analgesic effects [1]. - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis [1]. Group 2: Market Situation - As of the announcement date, 15 companies in China have obtained the Drug Registration Certificate for Loxoprofen Sodium Gel Patch, including listed companies such as Jiutian Pharmaceutical, Darentang, and China Resources Sanjiu [3]. - According to Moen Pharmaceutical data, the total hospital sales of Loxoprofen Sodium Gel Patch reached 1.349 billion yuan in the first three quarters of 2025, with retail sales in physical pharmacies amounting to 142 million yuan in the first half of 2025 [3]. Group 3: Impact on the Company - The approval of Loxoprofen Sodium Gel Patch enriches the company's product line for orthopedic diseases and enhances its competitiveness in the market, potentially improving overall profitability [4]. - The company has invested a total of 7.0366 million yuan in the drug project, including research and development and technology transfer [2]. - The company emphasizes the importance of drug research and development, maintaining strict quality control in the drug development, manufacturing, and sales processes [4].